10x Genomics
TXG
51.80
-5.58
-9.72%
10x Genomics
US · TXG
#1311 by market cap
Listed 2019
51.80
-5.58
-9.72%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
C
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1 1
■ Upgrades■ Downgrades
- 1 upgrade vs 1 downgrade among tracked analyst rating changes.
- Most recent: William Blair moved from Hold to Buy on 2026-04-20.
Analyst consensus 13 analysts
Buy
Avg price target 76.27 +47.2%
Price target rangecurrent 51.80
Low60.00
Avg76.27
High110.00
Buy 38%
Hold 62%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-11 | Stephens | -- | Hold | 65.00 |
| 2026-11-09 | UBS | -- | Hold | 61.00 |
| 2026-11-09 | Barclays | -- | Buy | 70.00 |
| 2026-11-09 | J.P. Morgan | -- | Hold | 65.00 |
| 2026-11-06 | CCORF | -- | Buy | 100.00 |
| 2026-11-06 | UBS | -- | Hold | 61.00 |
| 2026-11-06 | Piper Sandler | -- | Hold | 80.00 |
| 2026-11-06 | BofA Securities | -- | Hold | -- |
| 2026-11-06 | Stifel | -- | Buy | 68.00 |
| 2026-11-06 | Citi | -- | Hold | 60.00 |
| 2026-11-06 | Barclays | -- | Buy | 70.00 |
| 2026-11-05 | RBC Capital | -- | Hold | 70.00 |
| 2026-10-12 | CCORF | -- | Buy | 100.00 |
| 2026-10-09 | BofA Securities | -- | Hold | 80.00 |
| 2026-10-07 | Barclays | -- | Buy | 110.00 |
| 2026-09-29 | William Blair | -- | Buy | -- |
| 2026-09-29 | Leerink Partners | -- | Hold | 90.00 |
| 2026-09-25 | Argus Research | -- | Buy | 110.00 |
| 2026-09-01 | RBC Capital | -- | Hold | 70.00 |
| 2026-08-10 | CCORF | -- | Buy | 60.00 |
| 2026-08-07 | William Blair | -- | Buy | -- |
| 2026-08-07 | BofA Securities | -- | Hold | -- |
| 2026-08-07 | Jefferies | -- | Buy | 53.00 |
| 2026-08-07 | Stifel | -- | Buy | 50.00 |
| 2026-08-07 | Citi | -- | Hold | 50.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-04-20 | William Blair | Hold → Buy | -- |
| 2025-12-11 | Citi | Buy → Hold | 18.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-05 | After close | ±18.56% | +2.10% (in line) |
| 2026/Q2 | 2026-08-06 | After close | ±13.67% | +14.10% (beat) |
| 2026/Q1 | 2026-05-07 | After close | ±13.21% | -3.66% (in line) |
| 2025/Q4 | 2026-02-12 | After close | ±16.03% | +3.48% (in line) |
| 2025/Q3 | 2025-11-06 | After close | ±21.63% | +17.31% (in line) |
| 2025/Q2 | 2025-08-07 | After close | ±20.99% | -3.98% (in line) |
| 2025/Q1 | 2025-05-08 | After close | ±30.30% | +1.62% (in line) |
| 2024/Q4 | 2025-02-12 | After close | ±18.78% | -0.50% (in line) |
| 2024/Q3 | 2024-10-29 | After close | ±20.34% | +4.43% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±15.88% | +4.50% (in line) |
| 2024/Q1 | 2024-04-30 | After close | ±17.27% | -8.06% (in line) |
| 2023/Q4 | 2024-02-15 | After close | ±17.07% | +0.79% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
10x Genomics discussion 0 comments